- Global Pharma News & Resources

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drugs Pipeline Landscape Report 2021 -

DUBLIN--(BUSINESS WIRE)--The "Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) - Drugs In Development, 2021" report has been added to's offering.

Post-Polycythemia Vera Myelofibrosis - Drugs In Development, 2021, provides an overview of the Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 9, 20 and 11 respectively.

Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  1. Introduction
  2. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
  3. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Development
  4. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment
  5. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development
  6. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drug Profiles
  7. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects
  8. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products
  9. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
  10. Appendix

Companies Mentioned

  • AbbVie Inc
  • Acceleron Pharma Inc
  • Actuate Therapeutics Inc
  • Bristol Myers Squibb Co
  • Constellation Pharmaceuticals Inc
  • CTI BioPharma Corp
  • F. Hoffmann-La Roche Ltd
  • Geron Corp
  • Hangzhou East China Pharmaceutical Group Co Ltd
  • Imago BioSciences Inc
  • Incyte Corp
  • Italfarmaco SpA
  • JW Pharmaceutical Corp
  • Kartos Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Lynk Pharmaceutical Hangzhou Co Ltd
  • MEI Pharma Inc
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • NS Pharma Inc
  • Pharmaxis Ltd
  • Rhizen Pharmaceuticals SA
  • Samus Therapeutics Inc
  • Sierra Oncology Inc
  • Sino Biopharmaceutical Ltd
  • Sumitomo Dainippon Pharma Oncology, Inc
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Telios Pharma Inc

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 02-Sep-2021